Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
201lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
6 lessons
9mPolicyAdvanced
FDA's July 23 Peptide Panel Backed BPC-157, KPV, and TB-500. Here Is What Happens Next.
The FDA's peptide panel made its first moves on BPC-157, KPV, and TB-500. The vote matters, but the real story is what it changes next and what still has to happen before compounding pharmacies see any relief.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
9mResearchAdvanced
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access
After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
9mPolicyAdvanced
FDA Reclassifies 12 Peptides: What April 2026's Policy Shift Means for Biohackers
The FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
10mPolicyAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
After years of regulatory uncertainty, BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding access in 2026. Here's what the FDA reclassification means for peptide researchers.
9mResearchAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
14 peptides including BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding under FDA oversight. What changed, what it means for access, and what to expect next.
Also available at /blog for legacy links.